Characterization of zofenoprilat as an inducer of functional angiogenesis through increased H2 S availability. by Terzuoli, E et al.
RESEARCH PAPER
Characterization of
zofenoprilat as an inducer
of functional angiogenesis
through increased H2S
availability
E Terzuoli1*, M Monti1*, V Vellecco2, M Bucci2, G Cirino2, M Ziche1 and
L Morbidelli1
1Department of Life Sciences, University of Siena, Siena, Italy, and 2Department of Experimental
Pharmacology, University of Naples Federico II, Naples, Italy
Correspondence
Lucia Morbidelli, Department of
Life Sciences, University of Siena,
Via A. Moro 2, 53100 Siena, Italy.
E-mail: lucia.morbidelli@unisi.it
----------------------------------------------------------------
*These authors equally
contributed to the work.
----------------------------------------------------------------
Received
25 July 2014
Revised
13 January 2015
Accepted
22 January 2015
BACKGROUND AND PURPOSE
Hydrogen sulfide (H2S), an endogenous volatile mediator with pleiotropic functions, promotes vasorelaxation, exerts
anti-inflammatory actions and regulates angiogenesis. Previously, the SH-containing angiotensin-converting enzyme inhibitor
(ACEI), zofenopril, was identified as being effective in preserving endothelial function and inducing angiogenesis among
ACEIs. Based on the H2S donor property of its active metabolite zofenoprilat, the objective of this study was to evaluate
whether zofenoprilat-induced angiogenesis was due to increased H2S availability.
EXPERIMENTAL APPROACH
HUVECs were used for in vitro studies of angiogenesis, whereas the Matrigel plug assay was used for in vivo assessments.
KEY RESULTS
Zofenoprilat-treated HUVECs showed an increase in all functional features of the angiogenic process in vitro. As zofenoprilat
induced the expression of CSE (cystathionine-γ-lyase) and the continuous production of H2S, CSE inhibition or silencing
blocked the ability of zofenoprilat to induce angiogenesis, both in vitro and in vivo. The molecular mechanisms underlying
H2S/zofenoprilat-induced angiogenesis were dependent on Akt, eNOS and ERK1/2 cascades. ATP-sensitive potassium (KATP)
channels, the molecular target that mediates part of the vascular functions of H2S, were shown to be involved in the upstream
activation of Akt and ERK1/2. Moreover, the up-regulation of fibroblast growth factor-2 was dependent on CSE-derived H2S
response to H2S and KATP activation.
CONCLUSIONS AND IMPLICATIONS
Zofenoprilat induced a constant production of H2S that stimulated the angiogenic process through a KATP
channel/Akt/eNOS/ERK1/2 pathway. Thus, zofenopril can be considered as a pro-angiogenic drug acting through H2S release
and production, useful in cardiovascular pathologies where vascular functions need to be re-established and functional
angiogenesis induced.
Abbreviations
ACEI, angiotensin-converting enzyme inhibitor; CSE, cystathionine-γ-lyase; ECs, endothelial cells; FGF-2, fibroblast
growth factor-2; KATP, ATP-sensitive potassium; PAG, D-L-propargylglycine
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Introduction
Hydrogen sulfide (H2S) is endogenously synthesized in
various tissues by two different enzymes: cystathionine
β-synthase (CBS) and cystathionine γ-lyase (CSE), which use
L-cysteine as a substrate (Kamoun, 2004). CSE is responsible
for H2S production in the vasculature, although additional
pathways are involved. H2S is increasingly recognized as a
major player in several physiopathological conditions
related to the cardiovascular and nervous systems, inflam-
mation and cancer (Szabo, 2007; Szabo and
Papapetropoulos, 2011; Vandiver and Snyder, 2012). Endog-
enous H2S is recognized as a mediator of the angiogenic
response induced by VEGF (Papapetropoulos et al., 2009;
Szabo and Papapetropoulos, 2011; Coletta et al., 2012).
Recently, it has been demonstrated that H2S administration
to cultured endothelial cells (ECs) promotes proliferation,
migration and tube formation as well as in vivo angiogenesis
(Papapetropoulos et al., 2009; Szabo and Papapetropoulos,
2011; Polhemus et al., 2013). This H2S-mediated pro-
angiogenic effect is carried out both directly, by it acting on
vascular endothelium through both Akt and MAPK (p38
and ERK1/2) activation (Cai et al., 2007; Papapetropoulos
et al., 2009), and indirectly, due to the up-regulation of
VEGF and its receptors associated with the down-regulation
of angiogenesis inhibitors (endostatin, angiostatin and
parstatin) in vascular smooth muscle cells under hypoxic
conditions (Liu et al., 2010) and during myocardial infarc-
tion (Qipshidze et al., 2012).
We previously demonstrated a central role for fibroblast
growth factor (FGF-2) and its receptor FGFR1 in mediating
the acquisition of an angiogenic phenotype in coronary
microvascular endothelium (Donnini et al., 2006) by a
SH-containing ACEI (namely zofenoprilat), which has
been reported to exhibit both potent antioxidant and scav-
enger effects, and an anti-inflammatory action (Cominacini
et al., 2002). Zofenoprilat, but not other ACEI bearing (i.e.
captopril) or not (i.e. enalaprilat) a SH group, was most potent
and effective at promoting EC survival and ex vivo angiogen-
esis (Donnini et al., 2006; 2010). In microvascular endothe-
lium, zofenoprilat up-regulates eNOS, FGF-2 and telomerase
mRNA, induces cell survival, restores damaged ECs and pro-
motes angiogenesis (Donnini et al., 2006; 2010). Moreover,
zofenoprilat protected the coronary endothelium from
doxorubicin-induced injury through the up-regulation of
H2S/CSE (Monti et al., 2013).
Recently, H2S, spontaneously released by zofenoprilat
(both the S-isomer and the R-isomer), has been demon-
strated to account for the peripheral vascular effects of the
drug zofenopril, independently of ACE inhibition (Bucci
et al., 2014). The active drug metabolite behaved as a H2S
donor in a cell-free environment, slowly releasing H2S into
solution. Additionally, when the drug was administered in
vivo and the H2S evaluation was performed ex vivo, an
increased expression of CSE in vascular tissue (i.e. aorta) was
registered. Moreover, increased levels of H2S were found in
the plasma of SHRs, after zofenopril treatment (Bucci et al.,
2014).
Here, we investigated the contribution of H2S to the pro-
angiogenic effects induced by zofenoprilat in vascular
endothelium and the molecular mechanisms involved. In
our studies, zofenoprilat promoted angiogenesis in a
H2S/CSE-dependent manner in both in vitro and in vivo
models, through the activation of Akt, eNOS and ERK1/2
pathways downstream to ATP-sensitive potassium (KATP)
channel opening. Moreover, zofenoprilat increased cell–cell
junction organization and reduced the increase in endothe-
lial permeability induced by VEGF, a feature dependent on
CSE activity and H2S availability. Our data clearly indicate
that the ACEI zofenoprilat is a pro-angiogenic drug produc-
ing functional vessels dependent on H2S release, a peculiar-
ity that can explain its off-target protective effect, in
addition to its ability to inhibit ACE and control vascular
tone.
Tables of Links
TARGETS
Ion channelsa Enzymesb
KATP channel Akt (PKB)
Cystathionine β-synthase (CBS)
Cystathionine-γ-lyase (CSE)
Endothelial (e) NOS
ERK1
ERK2
MEK
p38 MAPK
PI3K
LIGANDS
Captopril Nitric oxide (NO)
Enalapril Phalloidin
Enalaprilat Propargylglycine (PAG)
FGF-2 U0126
Glibenclamide VEGF
L-cysteine Zofenopril
L-NAME Zofenoprilat
NaHS
These Tables list key protein targets and ligands in this article which are hyperlinked to corresponding entries in http://
www.guidetopharmacology.org, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY (Pawson et al., 2014) and are
permanently archived in the Concise Guide to PHARMACOLOGY 2013/14 (a,bAlexander et al., 2013a,b).
BJP E Terzuoli et al.
2962 British Journal of Pharmacology (2015) 172 2961–2973
Methods
Cell cultures
HUVECs were purchased from PromoCell (Heidelberg,
Germany) and were grown following the manufacturer’s
instructions. Cells were split 1:3 twice a week and used until
passage 10.
siRNA transfection
The siRNA sequence of human CSE (ID: s3712) and the
silencer negative control were from Ambion (Life Technolo-
gies, Paisley, UK) (Papapetropoulos et al., 2009; Suzuki et al.,
2011). A total of 1.5 × 105 cells were seeded in 6-well plates
and then transiently transfected using Lipofectamine 2000
(Life Technologies) according to the manufacturer’s instruc-
tions. Cells were assayed 48 h after transfection.
H2S measurement in culture media
H2S release in the conditioned media was measured via the
methylene blue assay (Stipanuk and Beck, 1982; Yang et al.,
2005; Bucci et al., 2010). Confluent cells were stimulated with
zofenoprilat (10 μM, 15 min, or 2, 4, 8 and 24 h) in the
presence/absence of actinomycin D (5 μg·mL−1). Trichloro-
acetic acid (10%) was added to the supernatants collected.
After protein precipitation, zinc acetate (1%) was added to the
supernatants, and then N,N-dimethylphenylendiamine
sulfate (20 mM) in 7.2 M HCl and FeCl3 (30 mM) in 1.2 M
HCl were supplemented to the reaction mixture, and absorb-
ance was measured after 20 min at a wavelength of 668 nm.
Adhesion assay
HUVECs were plated (4 × 104 cells per well) in 24-well plates
with test substances and incubated at 37°C for 40 min. The
culture medium was removed and adherent cells were fixed
with methanol, stained and randomly counted at 20×
magnification.
Wound assay
ECs were seeded into 24-well plates (1 × 105 cells per well) and,
after confluence, were treated with test substances for 18 h.
The assaywas carried out as previously reported (Terzuoli et al.,
2014). Results are expressed as percentage of wound area.
Proliferation assay
A total of 1 × 103 cells per well were seeded in 96 multiplates
and, after adherence (3–4 h), cells, silenced or not for CSE,
were treated with zofenoprilat (1–100 μM) or NaHS (6–60 μM)
in the absence or presence of D-L-propargylglycine (PAG)
(3 mM) or glibenclamide (10 μM). Cells were kept in culture
for 5 consecutive days, and zofenoprilat or NaHS was freshly
added every 2 days. In certain experiments, cells were exposed
to VEGF (20 ng·mL−1) for 48 h in the absence or presence of
zofenoprilat. Cells were then fixed, stained and randomly
counted at 20× magnification (Donnini et al., 2006).
In vitro angiogenesis model on Matrigel
HUVECs were silenced for CSE or pretreated with PAG (3 mM,
30 min) and then treated with zofenoprilat and other ACEIs
(10 μM, 18 h). Cells (7 × 104 cells per well of a 24 multi-well
plate) were then plated onto a thin layer (300 μL) of base-
ment membrane matrix (Matrigel; Becton Dickinson,
Waltham, MA, USA). Quantification of the tubular structures
after the staining with DY554-phalloidin (Thermo Fisher
Scientific, Waltham, MA, USA) was performed after 18 h as
previously published (Terzuoli et al., 2014).
Western blot
Cells (3 × 105 per 6 cm plate), at 90% of confluence, were
treated with either zofenoprilat with or without the pretreat-
ment with PAG (3 mM) or glibenclamide (10 μM) or L-NAME
(200 μM) or U0126 (10 μM) or LY294002 (10 μM) for 30 min.
Additionally, cells were stimulated with zofenoprilat (10 μM,
2, 4 and 24 h) in the presence/absence of actinomycin D
(5 μg·mL−1). ERK1/2, Akt, eNOS-Ser1177 phosphorylation and
CSE or FGF-2 expression were evaluated by Western blot
(Donnini et al., 2006; Monti et al., 2010).
Measurement of permeability
Cells were seeded on collagen-coated insert membranes
(Corning, Sigma-Aldrich, St. Louis, MO, USA) containing a
high density of 0.4 μm-diameter pores, and the inserts were
placed into a 12 multi-well plate. Cells were seeded at 8 × 104
cells per insert and cultured for 72 h. Confluent monolayers
were pretreated for 18 h with zofenoprilat and then VEGF
(20 ng·mL−1, 8 h) was added where indicated. FITC-dextran,
40 kDa, (10 μM) was used as fluorescent marker of permeabil-
ity, which was evaluated after 20 min by measuring the
fluorescence in a plate reader (Tecan, Mannedorf, Switzer-
land), at 485 and 535 nm excitation and emission respec-
tively (Terzuoli et al., 2014).
Immunofluorescence analysis
Vascular endothelial cadherin (VE-cadherin) and zonula
occludens-1 (ZO-1) protein, expressed at the cell surface, were
visualized by confocal analysis. Cells, 5 × 104, were seeded
onto 1 cm round glass coverslips. After 24 h, cells were
washed and treated with the indicated stimuli. Immunofluo-
rescence analysis was performed as previously reported
(Monti et al., 2014; Terzuoli et al., 2014).
In vivo Matrigel angiogenesis assay
In vivo Matrigel angiogenesis assay was performed as previ-
ously described (Terzuoli et al., 2014). C57 male black mice
(20–25 g, 25 animals) were kept in temperature- and
humidity-controlled rooms (22°C, 50%) with lights on from
07:00 to 19:00 h, andwater and food available ad libitum. Mice
were s.c. injected in the dorsal midline region with 0.4 mL of
Matrigel (Becton Dickinson, Franklin Lakes, NJ, USA) alone or
with stimuli. After 15 days, mice were killed by CO2 inhalation
and implants harvested. Plugs were re-suspended in 1 mL of
Drabkin’s reagent (Sigma-Aldrich) for 18 h on ice, and haemo-
globin concentration was determined by absorbance at
540 nm and compared with a standard curve (Sigma-Aldrich).
Materials and reagents
Cell culture reagents, NaHS, PAG, L-NAME, glibenclamide
and N,N-dimethylphenylendiamine sulfate, FeCl3, zinc
acetate and actinomycin D were from Sigma-Aldrich, while
U0126 and LY294002 were from Calbiochem (Milan, Italy).
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FBS was from Hyclone (Euroclone, Milan, Italy). Hoechst
33342, 40 kDa FITC-dextran, Lipofectamine 2000, scramble
and CSE silencing sequences were from Life Technologies
(Carlsbad, CA, USA). Trichloroacetic acid was purchased from
Carlo Erba (Arese, Milan, Italy).
Anti-phospho-Akt (Ser473), anti-Akt, anti-phospho-ERK1/2,
anti-ERK1/2 and anti-phospho-eNOS (Ser1177) antibodies were
obtained from Cell Signaling (Celbio, Milan, Italy). Anti-CSE
and anti-β-actin were from Sigma-Aldrich. Anti-FGF-2 anti-
body was from Upstate (Millipore, Vimodrone, Milan, Italy).
Anti-ZO-1 was from BD Transduction Laboratories (Milan,
Italy). Anti-VE-cadherin was from E-Bioscience (San Diego,
CA, USA). VEGFwas from R&D Systems (Milan, Italy). Zofeno-
prilat, captopril, enalapril and R-isomer were kindly provided
by Menarini Group (Florence, Italy).
Animal welfare and ethical statements
All procedures were carried out in accordance with the Italian
law (No. 116, 27 January 1992), which reflects the European
Directive 2010/63/UE, were approved by the University of
Siena Ethical Board and the Italian Ministry of Health. All
efforts were made to minimize the number of animals used
and their suffering. All studies involving animals are reported
in accordance with the ARRIVE guidelines for reporting
experiments involving animals (Kilkenny et al., 2010;
McGrath et al., 2010).
Data analysis and statistical procedures
Results are either representative or average of at least three
independent experiments performed in triplicate. Statistical
analysis was performed using ANOVA test, followed by Bonfer-
roni’s test and Student’s t-test when appropriate (GraphPad,
GraphPad Software, La Jolla, CA, USA). P < 0.05 was consid-
ered statistically significant.
Results
Zofenoprilat promotes angiogenesis in
human ECs
As has been previously demonstrated, zofenoprilat induced
angiogenesis in coronary post-capillary ECs (CVEC; Donnini
et al., 2006). Exposure of HUVECs to increasing concentra-
tions (1–100 μM) of zofenoprilat, consistent with that
achieved in vivo (Evangelista and Manzini, 2005), promoted
cell adhesion, migration and growth, with a maximal effect at
10 μM (Figure 1A–C). Analogue effects were obtained when
an exogenous source of H2S was added, administered to the
cells as NaHS (Figure 1D–F). However, VEGF, in the same
experimental conditions, was more effective (Figure 1D–F).
Similar data, in the proliferation assay, were obtained with
the R-isomer, the inactive diastereoisomer of zofenoprilat on
ACE activity (Supporting Information Fig. S1A). In the light
of these results, we selected 10 μM as the concentration of
zofenoprilat for the next experiments.
CSE-dependent H2S production mediates
zofenoprilat-induced in vitro
angiogenic activity
We evaluated the expression of CSE in HUVECs, and the
ability of zofenoprilat or its R-isomer to modulate its expres-
sion was also assessed. As shown in Figure 2A and Supporting
Information Fig. S1B, the endothelium constitutively
expressed CSE, and incubation with zofenoprilat further
increased it in a time-dependent manner, with a 3- to 3.5-fold
increase versus control at 18 and 24 h respectively
(Figure 2A). Enhanced CSE expression was confirmed when
the R-isomer was used (Supporting Information Fig. S1B). As
reported by Monti et al. (2013), captopril did not reproduce
this effect (0.125-fold increase vs. control). Therefore, as
zofenoprilat has been shown to have spontaneous H2S donor
activity (Bucci et al., 2014), exposure of HUVECs to zofeno-
prilat resulted in the accumulation of H2S in the culture
medium after 15 min, which was maintained for up to 8 h
and further increased at 24 h (Figure 2B).
Moreover, to determine the importance of the modula-
tion of CSE expression in acute and chronic treatment, meas-
urement of H2S in the presence of zofenoprilat was performed
in the presence and absence of the transcriptional inhibitor
actinomycin D at different time points from 2 to 24 h. As
shown in Figure 2C and D, expression of CSE and accumula-
tion of H2S by zofenoprilat was reduced in a time-dependent
manner in the presence of actinomycin D at 4 and 18 h and
at 8 and 24 h respectively. These data document the continu-
ous availability of H2S resulting from zofenoprilat initially
behaving as a H2S donor and later through an up-regulation
of CSE.
In the next experiments, the biosynthesis of H2S was
prevented through the pharmacological inhibition of CSE
by PAG or CSE silencing (Papapetropoulos et al., 2009).
The pre-incubation of HUVECs with PAG (3 mM) com-
pletely impaired zofenoprilat-induced angiogenic effects
(adhesion, migration and proliferation) (Figure 3A–C). Also,
the activity of the R-isomer of zofenoprilat on cell prolif-
eration was dependent on H2S formation (Supporting Infor-
mation Fig. S1A). In addition, the anti-angiogenic effect of
PAG on zofenoprilat-mediated angiogenesis was evident in a
three-dimensional differentiation model. When plated in a
thin layer of Matrigel and stimulated with zofenoprilat,
HUVECs assembled into a network of capillary-like tubes
(Figure 3D, panel b vs. panel a, and panel e for quantifica-
tion). Pretreatment of ECs with PAG completely inhibited
all these effects (Figure 3D). Similar effects were observed
with the R-isomer of zofenoprilat (Supporting Information
Fig. S1C). The effects of other ACEIs, such as captopril
and enalaprilat (10 μM), on the main angiogenic function
(proliferation and tube formation) were also evaluated. Both
compounds were less effective at inducing angiogenic
features than zofenoprilat (Supporting Information Fig. S2A
and B). Of note, the SH-containing ACEI captopril partially
acted through CSE-derived H2S, as shown from the
pretreatment with PAG (Supporting Information Fig. S2A
and B).
To corroborate the role of endogenous H2S on angiogen-
esis, we next used a siRNA approach to selectively impair H2S
production in ECs. The CSE mRNA silencing blunted CSE
protein expression (Figure 4A), leading to an attenuation of
the proliferation (Figure 4B) and capillary-like formation in
Matrigel (Figure 4C, panel d vs. panel b) in response to
zofenoprilat treatment.
These results demonstrate that endothelial CSE contrib-
utes to H2S release from zofenoprilat-treated endothelium
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and that zofenoprilat-derived H2S is necessary to stimulate
angiogenesis.
Effect of zofenoprilat-derived H2S on the
activation of angiogenic signalling pathways
In coronary post-capillary venules, it has been demonstrated
that zofenoprilat acts through Akt/eNOS/ERK1/2/FGF-2 acti-
vation (Donnini et al., 2006; 2010). Here, we confirmed the
activation of this pathway by zofenoprilat in HUVECs. In
particular, zofenoprilat was able to induce, in a time-
dependent manner, the phosphorylation of Akt, eNOS
(Ser1177) and ERK1/2, with a maximal effect at 15 min, while
there was no activation of p38 (data not shown).
Pre-incubation with PAG (3 mM, 30 min) completely
inhibited the activation of both phospho-Akt and ERK1/2
(Figure 5A), demonstrating the crucial role of zofenoprilat-
induced released of H2S in the promotion of these early
signals. Accordingly, the genetic ablation of endogenous CSE
protein significantly inhibited Akt and ERK1/2 phosphoryla-
tion (Figure 5B).
As previously demonstrated in CVEC (Donnini et al.,
2006; 2010), zofenoprilat promoted activation of the Akt-
dependent eNOS pathway in HUVECs. eNOS phosphoryla-
tion induced by zofenoprilat was under the control of CSE
activity (Figure 5C). Then, eNOS activation governed ERK1/2,
but not Akt phosphorylation, as demonstrated by the treat-
ment with L-NAME (200 μM, Figure 5D). This signalling
pathway was confirmed by the finding that pretreatment of
cells with U0126 (10 μM), a MEK inhibitor, did not modify
eNOS Ser1177 phosphorylation (Figure 5E). Conversely, pre-
treatment with LY294002 (10 μM), a PI3K inhibitor, signifi-
cantly reduced eNOS Ser1177 phosphorylation induced by
zofenoprilat (Figure 5E).
Finally, zofenoprilat, as previously demonstrated in
microvascular endothelium (Donnini et al., 2010), induced
an up-regulation FGF-2, which we demonstrated here to be
under the control of CSE/H2S availability (Figure 5F).
Since the vascular functions of H2S have been associated
with the ATP-dependent K+ channel (Zhao et al., 2001;
Papapetropoulos et al., 2009), its role in the occurrence of
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Figure 1
Effect of zofenoprilat and NaHS on EC adhesion, migration and proliferation. Evaluation of adhesion (40 min) (A and D), migration (18 h) (B and
E) and proliferation (5 days) (C and F) in HUVECs in the presence of zofenoprilat (1–100 μM) (A–C) or NaHS (6–60 μM) (D–F). Data in panels (A),
(C), (D) and (F) represent counted cells per well. Data in panels (B) and (E) are % area of wound, representing the complement of
healing/migration at 18 h with respect to time 0. VEGF (20 ng·mL−1) was used as a control. n = 3. *P < 0.05, **P < 0.01, ***P < 0.001 versus
untreated cells.
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angiogenesis was investigated. HUVECs, expressing KATP
channels (Papapetropoulos et al., 2009), were pretreated for
30 min with glibenclamide (10 μM), and Akt and ERK1/2
phosphorylation was evaluated by Western blot. Figure 6A
shows that the pharmacological block of KATP channels par-
tially impaired Akt and ERK1/2 activation, suggesting the
involvement of this transport system in H2S-induced actions.
Furthermore, the involvement of KATP in FGF-2 expression
was evaluated and the results showed that this endogenous
growth factor is also under the partial control of this channel
(Figure 6B). From a functional point of view, blockade of KATP
channels in ECs by glibenclamide reduced the proliferation of
ECs induced by zofenoprilat as well as NaHS (Figure 6C).
All these data suggest that zofenoprilat induces the release
of H2S, which, in turn, activates KATP channels, which, in part,
control Akt and ERK1/2 phosphorylation, FGF-2 expression
and endothelial angiogenic behaviour.
Zofenoprilat, via CSE activation, promotes
in vivo angiogenesis and normalizes
endothelial monolayers
To further study the H2S-mediated angiogenic activity of
zofenoprilat in vivo, we used the Matrigel implant assay in
mice. Matrigel plugs, either with zofenoprilat alone or in the
presence of PAG, were s.c. injected in C57 black mice and
harvested after 15 days. Implants containing zofenoprilat
showed several branched structures throughout the implant
(Figure 7A, panel b vs panel a). Conversely, in implants in
which zofenoprilat and PAG were concomitantly adminis-
tered, total vascular volume was markedly reduced
Figure 2
Zofenoprilat increases CSE protein expression and H2S production. Expression of CSE (A) in HUVECs in control condition and after incubation with
zofenoprilat (10 μM) for the indicated times. The blot is representative of three with similar results. The ratio between CSE and actin is presented
below the blot. **P < 0.01, ***P < 0.001 compared with untreated cells. Production of H2S (B) was determined in control ECs and in response to
zofenoprilat (10 μM) stimulation for 15 min, 2, 4, 8 and 24 h. n = 3. **P < 0.01 versus untreated cells. (C) Expression of CSE in HUVECs in control
(Ctr) condition and in response to zofenoprilat (10 μM) in the presence and absence of actinomycin D (5 μg·mL−1) for 2 (a), 4 (b) and 18 (c) h.
The blot is representative of three with similar results. The ratio between CSE and actin is presented below the blot. ***P < 0.001 compared with
untreated cells. ###P < 0.01 versus zofenoprilat-treated cells. (D) Production of H2S was determined in response to zofenoprilat stimulation (10 μM)
in the presence and absence of actinomycin D (5 μg·mL−1) for 2 (a), 8 (b) and 24 (c) h. n = 3. **P < 0.01, ***P < 0.001 versus untreated cells;
#P < 0.05, ##P < 0.01 versus zofenoprilat-treated cells.
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(Figure 7A, panel d vs. panel b). Quantitative analysis of func-
tioning vessels by haemoglobin determination revealed that
zofenoprilat produced a 2.3-fold increase in blood content
compared with control, whereas administration of PAG
reduced it by 42% (Figure 7A, panel e).
However, when designing a pro-angiogenic strategy, the
quality and the morphology of newly formed vessels are
crucial parameters as well as the interaction of the stimulus
with known angiogenic factors. To pursue this aim, we per-
formed a proliferation assay to evaluate whether zofenoprilat
could interfere with VEGF. Exposing ECs treated with zofeno-
prilat (10 μM, 48 h) to a maximal concentration of VEGF,
expected to be found in an angiogenic environment
(20 ng·mL−1), ) did not enhance the pro-angiogenic response
(Table 1).
Since VEGF stimulated vasculature is characterized by
elevated permeability and leakage (Ferrara et al., 2003), there
is a strong demand for pharmacological strategies that are
able to produce functional angiogenesis (Cai et al., 2011;
Anisimov et al., 2013). In our experiments, zofenoprilat
inhibited VEGF-induced permeability in a H2S-dependent
manner (Figure 7B), indicating a potential beneficial role in
the normalization of vasculature. To confirm the capability
of zofenoprilat to reduce VEGF-mediated permeability,
VE-cadherin and ZO-1 protein expression and localization at
the cell–cell junction were evaluated in vitro. As shown in
Figure 7C and D (panels a), confluent HUVEC monolayers
expressed VE-cadherin and ZO-1 protein mainly at the cell–
cell contact. In the presence of VEGF, the contacts disap-
peared (panels b), while VE-cadherin and ZO-1 labelling was
restored by zofenoprilat (panels d of Figure 7C and D). The
protective effect of zofenoprilat was related to the availability
of CSE-dependent H2S, since PAG pre-incubation reversed the
protective effect of zofenoprilat, inducing cell retraction and
a reduction in VE-cadherin and ZO-1 protein labelling
(panels e of Figure 7C and D).
These data demonstrate that zofenoprilat has pro-
angiogenic activity mediated through the production of H2S,
Figure 3
Role of H2S production on in vitro angiogenesis in response to zofenoprilat. ECs were incubated with zofenoprilat (10 μM, 40 min or 5 days,
respectively), pretreated or not with PAG (3 mM, 30 min), and adhesion (A) or proliferation (B) were assessed. Data represent counted cells per
well. n = 3. *P < 0.05, **P < 0.01 versus untreated cells. #P < 0.05, ##P < 0.01 versus zofenoprilat-treated cells. Cell migration (C) was evaluated
using scratch wound healing assay on ECs treated with 0.1% FBS (a), zofenoprilat (10 μM, 18 h, b), PAG (3 mM, 30 min pretreatment, c) or
zofenoprilat with PAG (d). Representative pictures of wounded EC monolayers are shown. n = 3. Quantification (e) of cell migration presented as
% area of wound. ***P < 0.001 versus untreated cells; ##P < 0.01 versus zofenoprilat. (D) Pseudocapillary formation in Matrigel by ECs exposed
to 0.1% FBS (a), zofenoprilat (10 μM, b), PAG (3 mM, 30 min pretreatment, c) and PAG + zofenoprilat (d) after 18 h. Cells were labelled with
DY554-phalloidin, and quantification (e) of pseudocapillaries was performed by counting the numbers of complete circles per well. n = 3.
**P < 0.01 versus untreated cells; ##P < 0.01 versus zofenoprilat.
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which controls all the signalling pathways and functional
responses of the angiogenic vascular endothelium to produce
functional and normalized vessels.
Discussion and conclusions
In the last decade, our attention has been focused on a clini-
cally available highly lipophilic ACEI, zofenopril, whose
active metabolite zofenoprilat bears a SH group and displays
the unique properties, among other ACEIs, of promoting EC
survival and angiogenesis, beyond its vasoactive properties
(Donnini et al., 2006; 2010; Monti et al., 2013). Recently, it
has been demonstrated that zofenoprilat, the active metabo-
lite of zofenopril, spontaneously releases H2S in solution, and
that in an in vivo pathological model, such as the SHR,
zofenopril increases H2S levels in the vascular tissue and
plasma (Bucci et al., 2014).
The increased availability of H2S, induced by zofenoprilat,
prompted us to analyse the involvement of this gaseous
transmitter in the pro-angiogenic and protective effect of this
ACEI on endothelium using in vitro and in vivo experimental
models associated with angiogenesis. In HUVECs, all the
functional activities related to angiogenesis in response to
zofenoprilat were analysed. HUVECs exposed to zofenoprilat
showed an increase in cell adhesion, migration and prolifera-
tion, with maximal effects at 10 μM, as previously demon-
strated in coronary post-capillary endothelium (Donnini
et al., 2006; 2010). H2S, given exogenously as NaHS, repro-
duced all the effects seen with zofenoprilat. The zofenoprilat
R-isomer, a molecule that maintains the SH group but is
ineffective as an ACEI, replicated these pro-angiogenic
effects. This last finding supports the hypothesis that the
angiogenic effect induced by zofenoprilat is dependent upon
the presence of the SH group in its structure and its ability to
release H2S.
Experiments were carried out to further dissect the rela-
tionship between zofenoprilat-released H2S and the biosyn-
thetic pathway of this gaseous transmitter. The release of H2S
from vascular endothelium mainly involves CSE (Kamoun,
2004; Kimura, 2010). HUVECs constitutively express CSE,
which is further up-regulated by zofenoprilat and its
R-isomer, but not by captopril, as previously demonstrated in
CVEC (Monti et al., 2013). Moreover, experiments with the
transcriptional inhibitor actinomycin D showed how the
accumulation of H2S by zofenoprilat is related to gene tran-
scription as it is reduced in the presence of actinomycin D.
Another H2S donor drug has also been reported to have
this peculiar property (Ma et al., 2011). Furthermore, it has
recently been demonstrated that exogenous H2S significantly
increases the transcription and expression of CSE (Wang
et al., 2013). Zofenoprilat reacts with L-cysteine, the endog-
Figure 4
Effect of CSE silencing on in vitro angiogenesis induced by zofenoprilat. (A) Western blot analysis of CSE expression in ECs silenced for CSE and
treated for 24 h with zofenoprilat (10 μM). The ratio between CSE and actin is presented. ***P < 0.001 compared with scramble (Scr) cells. (B)
Proliferation of ECs transfected with Scr or CSE siRNA and stimulated with zofenoprilat. Data are expressed as cell number counted per well. **P
< 0.01 versus Scr siRNA-untreated cells; ##P < 0.01 versus Scr siRNA cells treated with zofenoprilat. (C) Network formation of ECs seeded on
Matrigel after transfection with Src siRNA in 0.1% FBS (a), or plus zofenoprilat (b), or with CSE siRNA in 0.1% FBS (c), or plus zofenoprilat (d) for
8 h. Cells were labelled with DY554-phalloidin, and quantification (e) of pseudocapillaries was performed by counting the number of complete
circles per well. n = 3. **P < 0.01 versus Scr siRNA-untreated cells; ##P < 0.01 versus Scr siRNA zofenoprilat-treated cells.
BJP E Terzuoli et al.
2968 British Journal of Pharmacology (2015) 172 2961–2973
enous substrate of CSE, to form adducts that are substrates of
CSE (Subissi et al., 1999). Thus, zofenoprilat acts not only as
a H2S donor but also as a substrate for CSE to produce H2S,
and is responsible for CSE up-regulation in endothelium, as
also recently demonstrated by Bucci et al. (2014). So, the
release of H2S and the peculiar structure of zofenoprilat create
a tonic release of the gaseous transmitter, an effect sustained
by the up-regulation of CSE. This mechanism maintains high
levels of H2S over time (15 min–24 h), justifying its involve-
ment in the complex angiogenic process. Nevertheless, the
exact mechanism for the up-regulation of CSE remains to be
elucidated.
By inhibiting or ablating CSE, all the functional responses
induced by zofenoprilat in HUVECs are impaired. EC prolif-
eration, migration and organization of networks are indeed
blocked, as well as all the signalling pathways associated with
them. These findings strongly support the notion that the
off-target actions of this drug are exerted by the SH moiety
directly on vascular endothelium.
It is now clear that exogenous and endogenous H2S,
which can be induced by VEGF, is a stimulator of the angio-
genic responses in cultured endothelium and in different
angiogenic models in vivo. From a mechanistic point of view,
previous reports demonstrated that H2S stimulates Akt,
ERK1/2 and p38 in ECs and induces eNOS activation through
phosphorylation of Ser1177 and dephosphorylation of Thr495
(Cai et al., 2007; Osipov et al., 2009; Papapetropoulos et al.,
2009; Coletta et al., 2012). In HUVECs and in rat aortic vas-
Figure 5
Zofenoprilat-derived H2S activates signalling pathways associated with angiogenesis. (A and B) Western blot analysis of phosphorylated Akt and
ERK1/2 in ECs treated for 15 min with zofenoprilat (10 μM), pretreated or not with PAG (3 mM, 30 min) (A) or transfected with Src or CSE siRNA
(B). n = 3. The ratio between pAKT or pERK1/2 and AKT or ERK1/2, respectively, is presented below the blots. ***P < 0.001 compared with
untreated cells; #P < 0.05, ##P < 0.01, ###P < 0.001 compared with zofenoprilat-treated cells. (C) Western blot analysis of phosphorylated eNOS
in Ser1177 in ECs treated for 15 min, with zofenoprilat (10 μM), pretreated or not with PAG (3 mM, 30 min). The ratio between peNOS Ser1177 and
eNOS is reported. ***P < 0.001 compared with untreated cells; ###P < 0.001 compared with zofenoprilat-treated cells. (D) Akt and ERK1/2
phosphorylation evaluated in cells pretreated with L-NAME (200 μM, 30 min) and then stimulated with zofenoprilat (10 μM, 15 min). Blots are
representative of three with overlapping results. The ratio between pAKT or pERK1/2 and AKT or ERK1/2, respectively, is presented below the blots.
***P < 0.001 compared with untreated cells; #P < 0.05 compared with zofenoprilat-treated cells. (E) Western blot analysis of phosphorylated eNOS
in Ser1177 in ECs treated for 15 min with zofenoprilat (10 μM), pretreated or not with U0126 (10 μM, 30 min, top blot) or LY294002 (10 μM,
30 min, bottom blot). The ratio between peNOS Ser1177 and eNOS is presented below the blot. ***P < 0.001 compared with untreated cells; ###P
< 0.001 compared with zofenoprilat-treated cells. (F) Western blot analysis of FGF-2 expression in ECs treated for 18 h with zofenoprilat (10 μM),
pretreated or not with PAG (3 mM, 30 min). The ratio between FGF-2 and actin is presented below the blot. ***P < 0.001 compared with untreated
cells; ###P < 0.001 compared with zofenoprilat-treated cells.
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orelaxation, the two gaseous transmitters H2S and NO coop-
erate in the fine control of vascular functions (Bucci et al.,
2012; 2014; Coletta et al., 2012). In our experiments, the
molecular mechanisms underlying the H2S/zofenoprilat-
induced angiogenic phenotype in HUVECs are dependent on
Akt, eNOS-Ser1177 and ERK1/2. These results confirm data
previously obtained in CVEC (Donnini et al., 2006; 2010),
indicating that H2S released by zofenoprilat is responsible
for the sequential activation of the Akt/eNOS/ERK1/2 signal-
ling pathway, which, in turn, controls the endogenous
up-regulation of FGF-2.
All the signalling cascades involved in the effect of
zofenoprilat seem to be dependent on activation of CSE, since
silencing or pharmacological blockade of CSE blunts the acti-
vation of Akt, eNOS-Ser1177 and ERK1/2 and expression of
FGF-2. Some of the vascular functions of H2S have been
attributed to the opening of the KATP channel (Zhao et al.,
2001; Zanardo et al., 2006; Li et al., 2011). ECs express KATP
channels both in the plasma membrane and in the intracel-
lular organelles (Katnik and Adams, 1997; Malester et al.,
2007). The influence of KATP channels on the angiogenic effect
of H2S is evident from the data showing that glibenclamide
abolishes p38 activation and EC mobility (Papapetropoulos
et al., 2009; Szabo and Papapetropoulos, 2011). In our model,
KATP channels were shown to be partially involved in the
upstream activation of Akt and ERK1/2 and the expression of
FGF-2, including the sulfhydration modification of cysteine
residues in the target downstream proteins, demonstrated to
enhance their activity (Mustafa et al., 2009; Yang et al., 2013).
In addition to these findings, zofenoprilat was found to
promote neovascularization of Matrigel plugs s.c. implanted
in mice. This effect was dependent on a functioning CSE
since the presence of PAG impaired the occurrence of angio-
genesis. The stimulation of an angiogenic response might,
however, acquire a negative feature when it is induced within
the tumour environment or in ischaemic diseases, resulting
in disorganized and highly permeable vessels (Jain, 2003; Cai
et al., 2011; Anisimov et al., 2013). We thus aimed to ascer-
tain whether zofenoprilat could cooperate or synergize with
angiogenic factors such as VEGF and how it could correct
endothelial hyperpermeability. Zofenoprilat did not potenti-
ate the EC responses in the presence of VEGF; the concentra-
tion of VEGF used was as high as that usually found in an
angiogenic environment. On the contrary, in the presence of
VEGF, zofenoprilat restored endothelial permeability to basal
levels. Inhibition of endothelial leakage (measured as perme-
ability induced by VEGF and expression/localization of
VE-cadherin and ZO-1 protein) is thus an additional positive
feature of zofenoprilat’s effect in the intervention against
cardiovascular diseases. All the related vessel normalization
Figure 6
KATP channels are involved in signalling pathways and proliferation induced by zofenoprilat. (A) Western blot analysis of phosphorylated Akt and
ERK1/2 in HUVECs treated for 15 min with zofenoprilat (10 μM) pretreated or not with glibenclamide (10 μM, 30 min). n = 3. The ratio between
pAKT or pERK1/2 and AKT or ERK1/2, respectively, is presented. ***P < 0.001 compared with untreated cells; #P < 0.05 compared with
zofenoprilat-treated cells. (B) Western blot analysis of FGF-2 in HUVECs treated for 18 h with zofenoprilat (10 μM) pretreated or not with
glibenclamide (10 μM, 30 min). n = 3. The ratio between FGF-2 and actin is presented. **P < 0.01 compared with untreated cells; ###P < 0.001
compared with zofenoprilat-treated cells. (C) Proliferation of ECs treated with zofenoprilat (10 μM) or NaHS pretreated or not with glibenclamide
(10 μM, 30 min). n = 3. ***P < 0.001 versus control (Ctr); ##P < 0.01, ###P < 0.001 versus zofenoprilat or H2S-treated cells.
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parameters were dependent on H2S production, but the exact
molecular mechanisms that control the restoration of
transendothelial junctions remain to be elucidated. Recently,
H2S has been demonstrated to exert a protective effect on
lung vascular hyperpermeability by scavenging reactive
oxygen species and activation of Akt (Wang et al., 2012);
these mechanisms cannot be excluded in our model.
In conclusion, H2S released from zofenoprilat stimulates
all the angiogenic properties of ECs through a KATP channel/
Akt/eNOS/ERK1/2/FGF-2 pathway. Moreover, zofenopril/
zofenoprilat induced CSE to generate H2S, a property
exclusive to this drug with respect to other SH-containing
ACEI. This extra beneficial effect, beyond ACE inhibition,
could be helpful in cardiovascular pathologies where EC
functions and integrity need to be re-established and func-
tional angiogenesis induced.
Figure 7
Zofenoprilat/H2S promotes in vivo angiogenesis and controls endothelial hyperpermeability. (A) Representative plugs isolated after 15 days from
implant of Matrigel containing the following stimuli: none (a), 10 μM zofenoprilat (b), 3 mM PAG (c), zofenoprilat + PAG (d). (e) Quantitative
analysis of haemoglobin/angiogenesis in implants. For each condition (n = 6), the means ± SD are shown. **P < 0.01 versus untreated plugs; ##P
< 0.01 versus zofenoprilat-treated plugs. (B) Cell permeability was evaluated in HUVECs pretreated overnight with zofenoprilat (10 μM) or PAG
(3 mM), where indicated, and then treated with VEGF (20 ng·mL−1, 8 h). Results are expressed as fluorescent units ± SD. ***P < 0.001 versus
untreated cells; #P < 0.05, ###P < 0.001 versus VEGF; §P < 0.01 versus VEGF + zofenoprilat. (C and D) Immunofluorescence analysis of VE-cadherin
(C) and ZO-1 protein (D) in confluent HUVECs treated with the following stimuli: none (a), 20 ng·mL−1 VEGF (b), 10 μM zofenoprilat (18 h) (c),
zofenoprilat (18 h) + VEGF (8 h) (d), pretreatment for 30 min with 3 mM PAG + zofenoprilat (18 h) + VEGF for 8 h (e). Confocal images were taken
at 60× magnification. Scale bar = 10 μm.
Table 1
Effect of zofenoprilat on the angiogenic activation of endothelium by
VEGF
VEGF alone +Zofenoprilat
Proliferation 50 ± 8 52 ± 4
HUVECs were exposed to 20 ng·mL−1 VEGF in the absence or
presence of 10 μM zofenoprilat for 48 h. Proliferation data are
reported as % increase over control response, with 100% rep-
resenting the cell number counted in the basal condition (n = 3).
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Figure S1 Effect of R-isomer of zofenoprilat on endothelial
cell functionality. (A) Cell proliferation evaluated in HUVECs
treated with zofenoprilat R-isomer (10 μM, 5 days) in
presence/absence of PAG (3 mM, 30 min). Data are expressed
as counted cells/well. n = 3; **P < 0.01 versus untreated cells
and #P < 0.05 versus R-isomer. (B) CSE expression was evalu-
ated in HUVECs treated with R-isomer (10 μM) for indicated
times. The blot is representative of 3 with similar results. The
ratio between CSE over actin is reported. ***P < 0.001, com-
pared to untreated cells. (C) Pseudocapillary formation in
Matrigel by ECs exposed to 0.1% FBS (a), R-isomer (10 μM, b),
PAG (3 mM, pretreatment for 30 min, c), and PAG + R-isomer
(d) after 18 h. Quantification (e) of pseudocapillaries was
performed by counting the numbers of complete circles/well.
n = 3; ***P < 0.01 versus untreated cells, ###P < 0.01 versus
R-isomer.
Figure S2 Effect of captopril and enalaprilat on angiogenic
parameters. (A) HUVECs were treated with captopril or enal-
aprilat (10 μM) with or without PAG (3 mM, 30 min pretreat-
ment). Data are expressed as counted cells/well after 5 days of
incubation. n = 3; *P < 0.01 versus untreated cells and #P <
0.05 versus R-isomer. (B) Evaluation of network formation of
ECs seeded on Matrigel: 0.1% FBS (a), captopril (b), PAG (c),
enalaprilat (d) and captopril + PAG (e). Quantification (f) of
pseudocapillaries was performed by counting the numbers of
complete circles/well. n = 3; **P < 0.01 versus untreated cells.
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